HomeCompanion AnimalsSouth Korea Companion-Animal Drug Regulation: Cell Therapies and Extracellular Vesicles Emerge as...

South Korea Companion-Animal Drug Regulation: Cell Therapies and Extracellular Vesicles Emerge as Key Areas

Advanced veterinary therapies attract increasing regulatory attention

Advanced therapeutics are becoming an increasingly important area of veterinary pharmaceutical development, particularly in companion-animal medicine.

Cell-based products, extracellular vesicles and veterinary oncology medicines represent three areas with significant research and commercial potential. South Korea taking the lead in advancing review guidance in these categories.

Why these regulatory categories matter

1. Veterinary cell therapies – Cell-based products require specialised manufacturing and quality controls. Regulatory assessment generally needs to address:

  • Cell identity and characterisation.

  • Purity and viability.

  • Manufacturing consistency.

  • Potency and biological activity.

  • Contamination control.

  • Product stability.

  • Clinical safety and efficacy.

2. Extracellular vesicles – Extracellular vesicles are membrane-bound particles released by cells and are being investigated for their role in intercellular communication. Their potential veterinary applications include tissue repair, inflammation modulation and regenerative medicine.

However, they require robust product characterisation, manufacturing controls and clinical evidence.

3. Veterinary oncology – Cancer is an important clinical challenge in ageing companion animals. Advanced veterinary oncology development includes targeted medicines, immunotherapies and biological interventions.

Implications for the veterinary biotechnology industry

A well-defined regulatory pathway could encourage investment in veterinary biotechnology, improve product development planning and support commercialisation of advanced veterinary therapies.

For international companies, regulatory clarity is especially important when evaluating market entry, manufacturing partnerships and clinical-development requirements.

South Korea is a market worth monitoring for veterinary biotechnology, particularly cell-based therapeutics and companion-animal oncology.

Animal Health India Editorial Team
Animal Health India Editorial Teamhttps://animalhealthindia.com
Animal Health India (AHI) is an independent news and intelligence platform covering the global animal health, veterinary, livestock, poultry, companion animal and pet food sectors. Our editorial team comprises veterinary journalists, animal health professionals, regulatory affairs specialists and industry analysts with over 30 years of combined experience covering India, Asia, Europe and North America. AHI publishes news, regulatory updates, market intelligence and company news drawn from primary sources including DAHD, EMA, USDA, AVMA and leading veterinary publications worldwide.
RELATED ARTICLES